Lupin completes its acquisition of GAVIS in the US

Acquisition enhances Lupin’s scale in the US generic market and broadens Lupin’s pipeline in dermatology, controlled substance products and other high-value and niche generics.

New Jersey-based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products. GAVIS has 62 ANDA filings pending approval with FDA and a pipeline of more than 65 products under development. Seventy- two percent of these filings pending approvals represent niche dosage forms with 18 Para IVs and 8 First-to-File (FTF) products. GAVIS’s pending approvals address a market of over USD 9 billion.

The combined company will have a portfolio of over 120 in-market products, over 185 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the 5th largest pipeline of ANDA filings with FDA, addressing a USD 63.8 billion market.

Lupin has 37 FTF products, which includes 17 exclusive FTF opportunities. Lupin and Gavis combined will now have over 45 FTFs.

Commenting on the transaction, Ms. Vinita Gupta, CEO, Lupin Limited said: “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as specialty pipeline.”